Georgitis J W, Meltzer E O, Kaliner M, Weiler J, Berkowitz R
Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA.
Ann Allergy Asthma Immunol. 2000 Apr;84(4):451-9. doi: 10.1016/S1081-1206(10)62280-6.
Medications containing a combination antihistamine-decongestant are commonly used for allergic rhinitis yet onset-of-action comparisons for symptom relief after a single dose have not been performed.
To determine the onset of symptom relief and efficacy of antihistamine-decongestant medications (acrivastine-pseudoephedrine and loratadine-pseudoephedrine) compared with placebo in an outdoor park.
This study was conducted during the spring of 1997 using a double-blind, placebo-controlled design. Patients completed baseline rhinitis symptom diaries from 7:30 to 9:30 AM. Subjects with qualifying symptom scores received one dose of either acrivastine-pseudoephedrine, loratadine-pseudoephedrine, or placebo at 10:00 AM. Symptom diaries were recorded for the next 4 hours.
Of 593 patients randomized to treatment, 592 were included in efficacy analysis. Acrivastine-pseudoephedrine and loratadine-pseudoephedrine demonstrated a mean onset-of-action by 45 and 30 minutes respectively for total symptom and rhinitis symptom scores for the five sites. Onset-of-action for nasal congestion scores was 45 minutes for both medications. Sites having higher pollen exposure (>100 pollen grains over 6 hours) demonstrated a difference between the antihistamine combinations: acrivastine-pseudoephedrine had an onset of action at 45 minutes for total symptom and rhinitis symptom scores, and 15 minutes for nasal congestion scores whereas loratadine-pseudoephedrine had onset-of-action for nasal congestion score of 105 minutes but failed to reach significance at any timepoint for total symptom and rhinitis symptom scores.
Both antihistamine-decongestant combinations demonstrate an onset-of-action within 60 minutes of administration but under conditions of higher pollen exposure, the acrivastine combination was more effective for total symptoms, rhinitis symptoms, and nasal congestion with an onset-of-action within 45 minutes for rhinitis symptoms and 15 minutes for congestion.
含有抗组胺药 - 减充血剂组合的药物常用于过敏性鼻炎,但尚未进行单剂量用药后症状缓解起效时间的比较。
在户外公园中,确定抗组胺药 - 减充血剂药物(阿伐斯汀 - 伪麻黄碱和氯雷他定 - 伪麻黄碱)与安慰剂相比缓解症状的起效时间和疗效。
本研究于1997年春季采用双盲、安慰剂对照设计进行。患者在上午7:30至9:30完成基线鼻炎症状日记。符合症状评分标准的受试者于上午10:00接受一剂阿伐斯汀 - 伪麻黄碱、氯雷他定 - 伪麻黄碱或安慰剂。接下来的4小时记录症状日记。
在随机接受治疗的593例患者中,592例纳入疗效分析。阿伐斯汀 - 伪麻黄碱和氯雷他定 - 伪麻黄碱在五个部位的总症状和鼻炎症状评分的平均起效时间分别为45分钟和30分钟。两种药物的鼻充血评分起效时间均为45分钟。花粉暴露量较高(6小时内超过100个花粉颗粒)的部位显示出抗组胺药组合之间的差异:阿伐斯汀 - 伪麻黄碱在总症状和鼻炎症状评分方面的起效时间为45分钟,鼻充血评分为15分钟;而氯雷他定 - 伪麻黄碱的鼻充血评分起效时间为105分钟,但在总症状和鼻炎症状评分的任何时间点均未达到显著差异。
两种抗组胺药 - 减充血剂组合在给药后60分钟内均显示出起效,但在花粉暴露量较高的情况下,阿伐斯汀组合对总症状、鼻炎症状和鼻充血更有效,鼻炎症状起效时间在45分钟内,充血起效时间在15分钟内。